See the latest news and media coverage for Novartis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Innovative medicines company
novartis.comLast updated
In short: Novartis reported Q3 results amid clinical setbacks that erased market value and drew shareholder criticism.
Q3 core operating income rose 10% to USD 6 billion, driven by strong performance from priority brands including Kisqali and Kesimpta. A partial impairment of the del-desiran asset lowered reported operating income.
The EC approved the IL-17A inhibitor based on the Phase III REPLENISH trial results showing improved sustained remission rates versus placebo.
Rhapsido becomes the first treatment for symptomatic dermographism, expanding its indication beyond chronic spontaneous urticaria.
The therapy shows activity in secondary analyses. Novartis will analyze full data and consult regulators while advancing other neuromuscular programs.
The Swiss drugmaker increased its annual profit forecast as revenue from newer medications offsets losses from generic competition facing its former blockbuster Entresto.
On October 27, 2026, Novartis AG (NYSE: NVS) updated its full-year profit forecast, now expecting...
The experimental drug reduced relapse rates by 31-35%, missing the 50% target and lagging behind Roche's competitor treatment in late-stage trials.
The newspaper for business news, background analyses, currency and stock prices as well as investment recommendations.
Track Novartis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novartis and other trending companies.
